# NEWS R E L E A S E

## Ocumetics Begins Patient Recruitment for First-In-Human Clinical Study of Accommodating Intraocular Lens

**For Immediate Release**

**Calgary, Alberta – August 5, 2025** - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the commencement of patient recruitment for its highly anticipated first-in-human (“FIH”) study of the Ocumetics accommodating intraocular lens (the “Ocumetics Lens”). Patient recruitment is expected to be completed in approximately 7days.

“We are thrilled to begin recruiting patients for this historic study at our clinical partner site in Mexico City,” said Dean Burns, President and CEO of Ocumetics. “Our first-in-human clinical study will primarily assess the safety of the Ocumetics Lens and secondarily evaluate surgical technique, distance acuity and any accommodative effects. This is another significant step toward our goal of restoring clear distance and near vision without glasses after cataract surgery.”

Unlike traditional monofocal and multifocal intraocular lenses, the Ocumetics Lens is engineered to change its power in response to the brain’s attempt to visualize items in our environment at any distance.

Implantations will begin after patient recruitment, final site inspection, and surgeon training are completed. Results of the FIH clinical study will be instrumental in obtaining regulatory approval of larger, future studies and bringing the Ocumetics Lens to the market.

Ocumetics invites investors, partners, and the medical community to follow its progress as this landmark study unfolds.

**About Ocumetics**

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

**FOR FURTHER INFORMATION, PLEASE CONTACT:**


| | |
|---|---|
| Dean Burns | Roger Jewett |
| President and Chief Executive Officer | Chief Financial Officer |
| (817) 874-7564 | roger.jewett@ocumetics.com |


***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.